BioSpace News Archive

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 2:15 PM Eastern Time.

Veru Inc. announced that the Company has now filed both an amendment to its Annual Report on Form 10-K/A for the year ended September 30, 2023 as well as its Quarterly Report on Form 10-Q for the three months ended December 31, 2023.

Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today reported results for the fourth quarter and full year ended December 31,2023.

Korro Bio, Inc. announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer, Vineet Agarwal, and Chief Scientific Officer, Steve Colletti, Ph.D., will participate, present, and meet investors regarding progress of KRRO-110, Korro’s best-in-class candidate for AATD, at the following upcoming investor conferences:.

Poseida Therapeutics, Inc. announced that the Compensation Committee of its Board of Directors granted an inducement award to Syed Rizvi, M.D., the Company’s new Chief Medical Officer.

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2023.

Biomea Fusion, Inc. announced that on April 1, 2024, the compensation committee of Biomea’s board of directors granted two new employees non-qualified stock options to purchase an aggregate of 6,500 shares of the Company’s common stock.

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided an overview of recent operational highlights.

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its fourth quarter and fiscal year 2023, for the period ended December 31, 2023, on Tuesday, April 9, 2024, after the close of the market.